Table 6.
Cox proportional hazard regression models for time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) according to normocytic anemia and clinicopathological characteristics.
| TTR | CSS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| Tumor invasion (T1-T2 vs. T3-T4) | 1.92 | 0.94–3.91 | 0.073 | 1.26 | 0.65–2.44 | 0.495 | 1.10 | 0.67–1.80 | 0.720 |
| Nodal metastases (N0 vs. N1-N2) | 5.25 | 2.89–9.56 | <0.001 | 4.08 | 2.15–7.75 | <0.001 | 2.34 | 1.49–3.68 | <0.001 |
| Distant metastases (M0 vs. M1) | — | — | — | 6.77 | 3.94–11.6 | <0.001 | 4.30 | 2.68–6.89 | <0.001 |
| Tumor location (Colon vs. Rectum) | 1.46 | 0.78–2.74 | 0.236 | 0.93 | 0.54–1.60 | 0.791 | 0.91 | 0.57–1.44 | 0.679 |
| Preoperative radiotherapy or chemoradiotherapy (No vs. Yes) | 0.96 | 0.48–1.89 | 0.896 | 1.03 | 0.51–2.09 | 0.930 | 0.97 | 0.54–1.76 | 0.928 |
| Normocytic anemia (No vs. Yes) | 0.89 | 0.47–1.72 | 0.733 | 1.36 | 0.82–2.27 | 0.239 | 1.61 | 1.07–2.42 | 0.023 |
| mGPS (0 vs. 1–2) | 0.63 | 0.27–1.49 | 0.292 | 1.31 | 0.76–2.26 | 0.331 | 1.40 | 0.89–2.19 | 0.145 |
The models aimed to enlighten the prognostic value of normocytic anemia in CRC, relative to TNM variables and systemic inflammation (mGPS). Abbreviations: CI: confidence interval; CSS: cancer specific survival; HR: hazard ratio; mGPS: modified Glasgow Prognostic Score; OS: overall survival; TTR: time to recurrence.